About Prof. Zhou Qing
Prof. Zhou Qing (周清) is one of China's most prominent thoracic medical oncologists and clinical researchers, serving as Chief Physician, Doctoral Supervisor, Director of the Second Department of Pulmonary Oncology, and Deputy Director of the Guangdong Lung Cancer Institute (GLCI) at Guangdong Provincial People's Hospital (GDPH) in Guangzhou. As a core leader of the internationally celebrated research team founded by Prof. Wu Yi-Long, Prof. Zhou has played an instrumental role in establishing China's benchmark standards in lung cancer precision medicine.
Prof. Zhou serves as the Project Leader for the National Key Research and Development Program of China in lung cancer precision medicine. She is internationally recognized for her clinical expertise in rare oncogenic driver mutations (including RET fusions, MET alterations, and ROS1 rearrangements), dynamic resistance monitoring, and innovative salvage protocols for patients who develop acquired resistance to cancer immunotherapy.
Outpatient Consultation Schedule & Clinical Focus
Specialist Outpatient Clinic: Monday Morning & Wednesday Morning
Location: Guangdong Provincial People's Hospital (Dongchuan Main Hospital Campus / 东川总院, Guangzhou)
During her clinic sessions, Prof. Zhou provides specialized evaluations for complex thoracic oncology cases, focusing on:
- Targeted therapy for non-small cell lung cancer (NSCLC) harboring rare driver mutations (RET, MET, ROS1, BRAF, HER2, NTRK).
- Management of acquired resistance to first-, second-, and third-generation targeted kinase inhibitors.
- Salvage strategies and novel combination regimens for primary and acquired immunotherapy resistance.
- Screening and protocol enrollment for national and international multicenter clinical trials.
Core Clinical Specializations & Oncological Innovations
1. Rare Driver Mutations: RET, MET & ROS1 Precision Oncology
While standard lung cancer treatments primarily target EGFR and ALK mutations, patients with atypical alterations require specialized genomic interpretation and drug matching. Prof. Zhou commands extraordinary expertise across the rare mutation spectrum:
- RET Fusions: Extensive clinical leadership in managing advanced and post-surgical adjuvant RET-positive NSCLC, evaluating central nervous system (CNS) intracranial penetration and solvent-front resistance mutations.
- MET Alterations (Exon 14 Skipping & Amplification): Designing individualized regimens with selective MET inhibitors and combination protocols to overcome primary and secondary MET-driven disease progression.
- ROS1 Rearrangements: Formulating multi-line targeted algorithms that maintain prolonged disease remissions and intracranial disease control.
2. Overcoming Immunotherapy Resistance
Although immune checkpoint inhibitors have revolutionized lung cancer care, many patients experience secondary progression due to acquired immune escape, loss of neoantigen presentation, or immunosuppressive microenvironment shifts. Prof. Zhou leads cutting-edge research in reversing immunotherapy resistance, combining PD-1/PD-L1 inhibitors with anti-angiogenic agents, novel immunomodulators, bispecific antibodies, or personalized metronomic therapies to reignite the anti-tumor immune response.
3. Whole-Course Molecular Surveillance & Liquid Biopsy
Working at the forefront of translational oncology, Prof. Zhou integrates serial circulating tumor DNA (ctDNA) tracking and liquid biopsy profiling throughout each patient's care. This dynamic surveillance detects emerging resistant subclones months prior to radiographic progression, enabling preemptive therapeutic pivots that prevent explosive clinical relapse.
Academic Leadership, National Projects & Publications (2024–2026)
Prof. Zhou Qing is an internationally acknowledged clinical trial investigator whose work consistently appears in high-impact medical literature:
- National Key R&D Program Leader: Prof. Zhou serves as the Chief Principal Investigator leading a major project under China's National Key Research and Development Program, focusing on targeted precision therapeutics and overcoming drug resistance in solid tumors.
- High-Impact International Publications (2024–2026): As primary author and lead clinical investigator, Prof. Zhou has published landmark multicenter clinical trials in prestigious journals, including The Lancet Oncology and JAMA Oncology, evaluating next-generation targeted compounds for RET and MET alterations.
- CTONG Leadership: As an executive leader within the Chinese Thoracic Oncology Group (CTONG), she coordinates multicenter clinical trials across China, providing patients with access to the latest international therapeutic agents.
Guangdong Lung Cancer Institute (GLCI) Profile
Based at Guangdong Provincial People's Hospital in Guangzhou, the Guangdong Lung Cancer Institute represents a globally renowned academic center dedicated exclusively to thoracic oncology. Directed by Prof. Wu Yi-Long with Prof. Zhou Qing serving as Deputy Director, GLCI integrates dedicated clinical inpatient wards, an advanced Phase I-III clinical trial center, biobanking repositories, and comprehensive multidisciplinary tumor boards (MDTs) managing thousands of international and domestic cases annually.
Why International Patients Choose Prof. Zhou Qing
- Core Leadership in Asia's Leading Lung Cancer Center: Close collaboration with Prof. Wu Yi-Long ensures patients benefit from the highest standard of collective clinical intelligence.
- Sub-Specialized Authority in Rare Targets: Rare mutations (RET, MET, ROS1) are treated with world-leading precision, avoiding empirical chemotherapy when targeted options exist.
- Direct Pathway to Breakthrough Clinical Trials: Leading active Phase I-III trials, Prof. Zhou provides qualifying patients with early access to emerging next-generation therapeutics.
- Strategic Location in Guangzhou: Convenient international transit and fast-track outpatient appointments via CMCS concierge navigation.
The Patient Journey: Navigating Care with CMCS
China Medical Concierge – Shanghai (CMCS) coordinates seamless access for international patients consulting with Prof. Zhou Qing in Guangzhou:
- Step 1: Genomic & Clinical Dossier Evaluation: Patients securely transmit complete medical records, previous treatment timelines, NGS molecular panels, and imaging scans for pre-screening.
- Step 2: Pre-Arrival Strategy & Trial Matching: CMCS coordinates an initial case review with Prof. Zhou's team to identify candidate targeted agents, clinical trials, or resistance management plans.
- Step 3: Medical Visa, Transit & Accommodations: We issue medical visa invitation documentation, arrange airport greeting in Guangzhou, and coordinate executive lodging near the Dongchuan Main Hospital campus.
- Step 4: On-Site Medical Translation & Clinic Support: Dedicated bilingual medical liaisons accompany you to Monday or Wednesday morning clinic appointments, laboratory blood draws, imaging diagnostics, and pharmacy dispensations.
- Step 5: Post-Treatment Monitoring & Continuity of Care: CMCS coordinates remote follow-up between Prof. Zhou's clinical team and your home physicians to monitor tumor markers, scan results, and ongoing tolerance.
Frequently Asked Questions
When does Prof. Zhou Qing conduct outpatient clinics?
Prof. Zhou holds specialist outpatient clinics on Monday mornings and Wednesday mornings at the Dongchuan Main Hospital Campus (东川总院) of Guangdong Provincial People's Hospital in Guangzhou. Advance coordination and pre-arrival dossier review through CMCS are strongly recommended.
What can be done if my lung cancer has developed resistance to immunotherapy?
Immunotherapy resistance requires a thorough re-evaluation using liquid biopsy or repeat tissue biopsy. Prof. Zhou evaluates specific resistance mechanisms to formulate novel combination strategies—such as adding targeted anti-angiogenic agents, bispecific antibodies, or enrolling in ongoing clinical trials designed to reverse immune exhaustion.
How does Prof. Zhou evaluate rare mutations like RET or MET?
Using high-depth next-generation sequencing (NGS), Prof. Zhou assesses the exact genomic fusion partner or mutation subtype, concurrent co-mutations, and previous drug exposure to select targeted inhibitors with optimal systemic and intracranial efficacy.
How long should international patients plan to stay in Guangzhou?
An initial comprehensive outpatient consultation and molecular workup typically require 3 to 5 business days. If starting a new targeted medication or joining an active clinical trial, an initial stay of 1 to 2 weeks is recommended for observation and safety monitoring.
Schedule Your Consultation with Prof. Zhou Qing
If you or a loved one is seeking world-class expert consultation for lung cancer, rare driver mutations (RET, MET, ROS1), targeted therapy resistance, or immunotherapy failure, contact our medical concierge team today.
Contact CMCS Medical Concierge:
- Email: contract@medicalsh.com
- WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
- Website: www.medicalsh.com
0 commenti